PHASE II TRIAL TO INVESTIGATE EFFICACY AND SAFETY OF BENDAMUSTINE, DEXAMETHASONE AND THALIDOMIDE IN RELAPSED OR REFRACTORY MULTIPLE MYELOMA PATIENTS AFTER TREATMENT WITH LENALIDOMIDE AND BORTEZOMIB

被引：0
|
作者：
Mian, M.
Pescosta, N. [1 ]
Luminari, S. [2 ]
Badiali, S. [2 ]
Marcheselli, L. [2 ]
Patriarca, F. [3 ]
Zambello, R. [4 ]
Mondello, P. [5 ]
Pascarella, A. [6 ]
Pitini, V. [5 ]
Cortelazzo, S. [7 ]
机构：
[1] Hosp Bolzano, Bolzano, Italy
[2] Univ Modena & Reggio Emilia, Dept Hematol & Oncol, Modena, Italy
[3] Azienda Osped Univ, Udine, Italy
[4] Univ Padua, Sch Med, Padua, Italy
[5] Univ Messina, Messina, Italy
[6] Osped Angelo, Venice, Mestre, Italy
[7] Humanitas Gavazzeni Canc Ctr, Bergamo, Italy
来源：
HAEMATOLOGICA | 2014年 / 99卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
PB1648
引用
收藏
页码：637 / 637
页数：1
相关论文
共 50 条
  • [41] Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety
    Lee, Sung Sook
    Suh, Cheolwon
    Kim, Bong-Seog
    Chung, Jooseop
    Joo, Young-Don
    Ryoo, Hun-Mo
    Do, Young Rok
    Jin, Jong-Youl
    Kang, Hye Jin
    Lee, Gyeong-Won
    Lee, Moon Hee
    Shim, Hyeok
    Kim, Kihyun
    Yoon, Sung-Soo
    Bang, Soo Mee
    Kim, Ho Young
    Lee, Je-Jung
    Park, Jinny
    Lee, Dong Soon
    Lee, Jae-Hoon
    ANNALS OF HEMATOLOGY, 2010, 89 (09) : 905 - 912
  • [42] CLNICAL EFFICACY OF VEL-CTD (BORTEZOMIB, CYCLOPHOSPHAMIDE, THALIDOMIDE, AND DEXAMETHASONE) REGIMEN IN PATIENTS WITH RELAPSED OR REFRACTORY MULTIPLE MYELOMA: A PHASE II STUDY
    Kim, Y. K.
    Ahn, J. S.
    Yang, D. H.
    Sohn, S. K.
    Moon, J. H.
    Kim, H. J.
    Shin, H. J.
    Chung, J. S.
    Choi, Y. J.
    Chae, Y. S.
    Kim, J. G.
    Lee, J. H.
    Lee, J. J.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2009, 94 : 383 - 383
  • [43] Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study
    Kim, Yeo-Kyeoung
    Sohn, Sang-Kyun
    Lee, Jae-Hoon
    Yang, Deok-Hwan
    Moon, Joon-Ho
    Ahn, Jae-Sook
    Kim, Hyeoung-Joon
    Lee, Je-Jung
    ANNALS OF HEMATOLOGY, 2010, 89 (05) : 475 - 482
  • [44] Clinical efficacy of a bortezomib, cyclophosphamide, thalidomide, and dexamethasone (Vel-CTD) regimen in patients with relapsed or refractory multiple myeloma: a phase II study
    Yeo-Kyeoung Kim
    Sang-Kyun Sohn
    Jae-Hoon Lee
    Deok-Hwan Yang
    Joon-Ho Moon
    Jae-Sook Ahn
    Hyeoung-Joon Kim
    Je-Jung Lee
    Annals of Hematology, 2010, 89 : 475 - 482
  • [45] EFFICACY AND SAFETY OF LENALIDOMIDE AND DEXAMETHASONE IN PATIENTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA: A REAL LIFE EXPERIENCE
    Soyer, N.
    Patir, P.
    Uysal, A.
    Duran, M.
    Unal, H. D.
    Tombuloglu, M.
    Sahin, F.
    Vural, F.
    Saydam, G.
    LEUKEMIA RESEARCH, 2016, 49 : S36 - S36
  • [46] Pomalidomide, Bortezomib and Dexamethasone (PVD) for Patients with Relapsed Lenalidomide Refractory Multiple Myeloma (MM)
    Lacy, Martha Q.
    LaPlant, Betsy R.
    Laumann, Kristina M.
    Kumar, Shaji
    Gertz, Morie A.
    Hayman, Suzanne R.
    Buadi, Francis
    Dispenzieri, Angela
    Lust, John A.
    Kapoor, Prashant
    Leung, Nelson
    Russell, Stephen J.
    Dingli, David
    Gonsalves, Wilson I.
    Fonseca, Rafael
    Bergsagel, P. Leif
    Roy, Vivek
    Sher, Taimur
    Ailawadhi, Sikander
    Chanan-Khan, Asher
    Stewart, A. Keith
    Reeder, Craig B.
    Rajkumar, S. Vincent
    Mikhael, Joseph R.
    BLOOD, 2014, 124 (21)
  • [47] Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
    Shinsuke Iida
    Tatsuo Ichinohe
    Atsushi Shinagawa
    Kenshi Suzuki
    Naoki Takezako
    Masayuki Aoki
    International Journal of Hematology, 2018, 107 : 460 - 467
  • [48] Lenalidomide, bortezomib, and dexamethasone in relapsed/refractory multiple myeloma (MM): Encouraging outcomes and tolerability in a phase II study
    Anderson, K. C.
    Jagannath, S.
    Jakubowiak, A.
    Lonial, S.
    Raje, N.
    Alsina, M.
    Ghobrial, I.
    Knight, R.
    Esseltine, D.
    Richardson, P.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [49] Safety and efficacy of daratumumab in combination with bortezomib and dexamethasone in Japanese patients with relapsed or refractory multiple myeloma
    Iida, Shinsuke
    Ichinohe, Tatsuo
    Shinagawa, Atsushi
    Suzuki, Kenshi
    Takezako, Naoki
    Aoki, Masayuki
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2018, 107 (04) : 460 - 467
  • [50] Bortezomib in combination with bendamustine and preduisone in the treatment of patients with refractory/relapsed multiple myeloma
    Poenisch, Wolfram
    Bourgeois, Malvina
    Wang, Song-Yau
    Heyn, Simone F.
    Jaekel, Nadja
    Braunert, Leanthe
    Rohrberg, Robert
    Hurtz, Hans Juergen
    Hoffmann, Franz Albert
    Schwarzer, Andreas
    Becker, Cornelia
    Al Ali, Haifa
    Niederwieser, Dietger W.
    BLOOD, 2007, 110 (11) : 799A - 800A
12345